(Total Views: 48)
Posted On: 12/05/2024 3:05:16 PM
Post# of 77
NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Strategic Board Appointment
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in the development of inflammation and immunology (“I&I”) biological products and offering CDMO services through its Scinai Bioservices unit, today announced the appointment of Prof. Michael Schön to its Scientific Advisory Board (“SAB”). Recognized with numerous awards for his groundbreaking research on immune reactions in inflammation, Prof. Michael Schön is a distinguished professor and director of the Department of Dermatology, Venereology and Allergology at the University Medical Center Göttingen. He also serves as vice dean and deputy director for research and teaching and is the former director of the Lower Saxony Institute of Occupational Dermatology.
“We are thrilled to welcome Prof. Schön, a world-class expert in dermatology, particularly in psoriasis and atopic dermatitis, to our Scientific Advisory Board. Michael’s extensive experience as a dermatologist, having treated thousands of patients, and as a researcher with over 440 scientific publications in top-rated journals, along with his proven track record in drug development and clinical research, will be invaluable to Scinai,” said SCNI CEO Amir Reichman. “His insights will be crucial as we advance our pipeline of innovative I&I biological products. Additionally, I would like to congratulate Dr. Jonathan Sadeh , a member of our Scientific Advisory Board, on his recent appointment as Chief Scientific Officer and Chief Medical Officer of Bausch Health. We wish Jonathan great success in his new role. These two recent appointments to our Scientific Advisory Board are a testament to the high caliber of talent advising our R&D team and board of directors.”
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in the development of inflammation and immunology (“I&I”) biological products and offering CDMO services through its Scinai Bioservices unit, today announced the appointment of Prof. Michael Schön to its Scientific Advisory Board (“SAB”). Recognized with numerous awards for his groundbreaking research on immune reactions in inflammation, Prof. Michael Schön is a distinguished professor and director of the Department of Dermatology, Venereology and Allergology at the University Medical Center Göttingen. He also serves as vice dean and deputy director for research and teaching and is the former director of the Lower Saxony Institute of Occupational Dermatology.
“We are thrilled to welcome Prof. Schön, a world-class expert in dermatology, particularly in psoriasis and atopic dermatitis, to our Scientific Advisory Board. Michael’s extensive experience as a dermatologist, having treated thousands of patients, and as a researcher with over 440 scientific publications in top-rated journals, along with his proven track record in drug development and clinical research, will be invaluable to Scinai,” said SCNI CEO Amir Reichman. “His insights will be crucial as we advance our pipeline of innovative I&I biological products. Additionally, I would like to congratulate Dr. Jonathan Sadeh , a member of our Scientific Advisory Board, on his recent appointment as Chief Scientific Officer and Chief Medical Officer of Bausch Health. We wish Jonathan great success in his new role. These two recent appointments to our Scientific Advisory Board are a testament to the high caliber of talent advising our R&D team and board of directors.”
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Scroll down for more posts ▼
